BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28535103)

  • 1. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
    Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
    Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.
    Djatche LM; Goble JA; Chun G; Varga S
    J Manag Care Spec Pharm; 2018 Jan; 24(1):39-46. PubMed ID: 29290169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Tools in Managed Care Decision Making: Current Hurdles and Future Opportunities.
    Schafer J; Galante D; Shafrin J
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S21-S27. PubMed ID: 28535106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
    Waldeck AR; Botteman MF; White RE; van Hout BA
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are National Comprehensive Cancer Network Evidence Block Affordability Ratings Representative of Real-World Costs? An Evaluation of Advanced Non-Small-Cell Lung Cancer.
    Cohen JT; Lin PJ; Sheinson DM; Wong WB; Wu N; Yim YM; Ramsey SD
    J Oncol Pract; 2019 Nov; 15(11):e948-e956. PubMed ID: 31513478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
    Westrich K; Buelt L; Dubois RW
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.
    Frois C; Howe A; Jarvis J; Grice K; Wong K; Zacker C; Sasane R
    J Manag Care Spec Pharm; 2019 Feb; 25(2):246-259. PubMed ID: 30698093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer.
    Wong SE; Everest L; Jiang DM; Saluja R; Chan KKW; Sridhar SS
    JCO Oncol Pract; 2020 Feb; 16(2):e201-e210. PubMed ID: 32045549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Systematic Review of the Effect of Cancer Treatment on Work Productivity of Patients and Caregivers.
    Kamal KM; Covvey JR; Dashputre A; Ghosh S; Shah S; Bhosle M; Zacker C
    J Manag Care Spec Pharm; 2017 Feb; 23(2):136-162. PubMed ID: 28125370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
    Hanna N; Johnson D; Temin S; Baker S; Brahmer J; Ellis PM; Giaccone G; Hesketh PJ; Jaiyesimi I; Leighl NB; Riely GJ; Schiller JH; Schneider BJ; Smith TJ; Tashbar J; Biermann WA; Masters G
    J Clin Oncol; 2017 Oct; 35(30):3484-3515. PubMed ID: 28806116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the Clinical Application of the American Society of Clinical Oncology Value Framework: A Medicare Cost-Benefit Analysis in Chronic Lymphocytic Leukemia.
    Seymour EK; Schiffer CA; de Souza JA
    J Oncol Pract; 2017 Dec; 13(12):e1002-e1011. PubMed ID: 29144866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.